Febrile neutropenia risk assessment tool: Improving clinical outcomes for oncology patients
- 2 December 2013
- journal article
- research article
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 18 (2) , 167-174
Abstract
No abstract availableKeywords
Funding Information
- Amgen Ireland Limited
This publication has 36 references indexed in Scilit:
- Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysisBMC Cancer, 2011
- Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapySupportive Care in Cancer, 2011
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applicationsAnnals of Oncology, 2010
- Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Supportive Care in Cancer, 2010
- Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patientsBreast Cancer Research and Treatment, 2008
- Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOPAnnals of Hematology, 2007
- Evaluating the Total Costs of Chemotherapy-Induced Febrile Neutropenia: Results from a Pilot Study with Community Oncology Cancer PatientsThe Oncologist, 2007
- 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort studyBMJ, 2005
- Optimal Use of Granulocyte-Colony-Stimulating Factor in Patients With Cancer Who Are at Risk for Chemotherapy-Induced NeutropeniaOncology Nursing Forum, 2004